Pegylated liquisomes: A novel combined passive targeting nanoplatform of L-carnosine for breast cancer.

摘要: Abstract PEGylated Liquisomes (P-Liquisomes), a novel drug delivery system was designed for the first time by incorporating phospholipid complex in liquid crystalline nanoparticles (P-LCNPs). L-carnosine (CN), challenging dipeptide, has proven to be promising anti-cancer drug. However, it exhibits high water solubility and extensive in-vivo degradation that halts its use. The objective of this work investigate ability our improve CN anticancer activity prolonging it’s release protecting in-vivo. In-vitro appraisal revealed spherical light-colored vesicles encapsulated crystals, confirming successful formation combined system. P-Liquisomes were nano-sized (149.3 ± 1.4 nm), with ZP (-40.2 1.5 mV), complexation efficiency (97.5 0.9 %) outstanding sustained only 75.4 % released after 24 h, compared P-LCNPs Phytosomes. results obtained are considered as break through or Phytosomes alone, especially when dealing hydrophilic CN. cytotoxicity evaluation, superior cytotoxic effect (IC50 = 25.9) h incubation. Besides, proved non-toxic succeeded show chemopreventive manifested reduction of; tumor growth (7.1%), VEGF levels (14.3 pg/g tissue), cyclin D1 15.5 ng/g tissue elevation caspase-3 level (36.4 solution. Conclusively, succeded achieve maximum therapeutic outcome without altering might used other compounds.